TENX: התחייבויות שוטפות של החברה Tenax Therapeutics Inc.

Tenax Therapeutics (TENX) is implementing ESG principles, maintaining strict control over bioethics and safety during the development of cardiology treatments. An analysis of short-term debt resources helps avoid purchasing the asset at its peak, while 0.00 serves as the final level marker. High trial costs and dependence on the FDA create liquidity risks. Market capitalization is based on the development of therapies for pulmonary hypertension and cardiac pathologies.

Short-term debt measures the volume of current liabilities with a maturity of up to one year, determining the issuer's operational liquidity buffer and financial stability. By analyzing liabilities due within a year, an investor assesses the risk of funding shortages, which is critically important for Tenax Therapeutics (TENX) when financing the development of vital pulmonary hypertension therapies and expanding its cardiology ecosystem.